Answers are grounded in this paper and cite their sources.
INTRODUCTION: Discontinuation of denosumab can lead to a rebound increase in bone resorption, which may result in multiple vertebral fractures. Current guidelines recommend retreatment with denosumab or administration of zoledronate in this setting. MATERIALS AND METHODS: We report a series of 4 patients who developed vertebral fractures following denosumab withdrawal and were subsequently treated with romosozumab, a dual-action agent with anabolic and antiresorptive properties. RESULTS: All patients showed progressive improvement in BMD and microarchitecture, with suppression of bone turnover markers and no new clinical fractures during treatment and follow-up. DISCUSSION: Although limited by the uncontrolled design and small sample size, these observations suggest that romosozumab might be considered as a potential therapeutic approach for selected patients with post-denosumab rebound fractures.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: